|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
94 a.a.
|
 |
|
|
|
|
|
|
|
210 a.a.
|
 |
|
|
|
|
|
|
|
222 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system
|
 |
|
Title:
|
 |
Crystal structure of the fab yads1 complexed with h-vegf
|
|
Structure:
|
 |
Vascular endothelial growth factor a. Chain: v, w. Synonym: vegf-a, vascular permeability factor, vpf, h-vegf. Engineered: yes. Fab yads1 light chain. Chain: a, l. Engineered: yes. Fab yads1 heavy chain. Chain: b, h.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: vegf, vegfa. Expressed in: escherichia coli. Expression_system_taxid: 562. Mus musculus. House mouse. Organism_taxid: 10090.
|
|
Biol. unit:
|
 |
Hexamer (from
)
|
|
Resolution:
|
 |
|
2.60Å
|
R-factor:
|
0.215
|
R-free:
|
0.271
|
|
|
Authors:
|
 |
F.A.Fellouse,C.Wiesmann,S.S.Sidhu
|
Key ref:
|
 |
F.A.Fellouse
et al.
(2004).
Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.
Proc Natl Acad Sci U S A,
101,
12467-12472.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
09-Jul-04
|
Release date:
|
31-Aug-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P15692
(VEGFA_HUMAN) -
Vascular endothelial growth factor A, long form from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
395 a.a.
94 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
101:12467-12472
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.
|
|
F.A.Fellouse,
C.Wiesmann,
S.S.Sidhu.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Antigen-binding fragments (Fabs) with synthetic antigen-binding sites were
isolated from phage-displayed libraries with restricted
complementarity-determining region (CDR) diversity. Libraries were constructed
such that solvent-accessible CDR positions were randomized with a degenerate
codon that encoded for only four amino acids (tyrosine, alanine, aspartate, and
serine). Nonetheless, high-affinity Fabs (K(d) = 2-10 nM) were isolated against
human vascular endothelial growth factor (hVEGF), and the crystal structures
were determined for two distinct Fab-hVEGF complexes. The structures revealed
that antigen recognition was mediated primarily by tyrosine side chains, which
accounted for 71% of the Fab surface area that became buried upon binding to
hVEGF. In contrast, aspartate residues within the CDRs were almost entirely
excluded from the binding interface. Alanine and serine residues did not make
many direct contacts with antigen, but they allowed for space and conformational
flexibility and thus played an auxiliary role in facilitating productive
contacts between tyrosine and antigen. Tyrosine side chains were capable of
mediating most of the contacts necessary for high-affinity antigen recognition,
and, thus, it seems likely that the overabundance of tyrosine in natural
antigen-binding sites is a consequence of the side chain being particularly well
suited for making productive contacts with antigen. The findings shed light on
the basic principles governing the evolution of natural immune repertoires and
should also aid the development of improved synthetic antibody libraries.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Fig. 3. The structural epitope for binding to YADS1 (A) or
YADS2 (B) mapped on the molecular surface of hVEGF. The
structural epitope consists of hVEGF residues that make contact
with one or more residues of the Fab, with "contact" defined as
a distance <4.1 Å. Residues that contact the heavy or
light chain are colored green or yellow, respectively. The
dashed line outlines the structural epitope for binding to
Flt-1[D2], as determined from a previously described x-ray
structure (PDB code 1FLT [PDB]
) (34).
|
 |
Figure 5.
Fig. 5. The CDR side chains of YADS1 (A) and YADS2 (B) that
contact hVEGF. The structural epitope for binding to the Fab
(see Fig. 3) was mapped onto the molecular surface of hVEGF, and
residues that made contacts with tyrosines or other residue
types are colored orange or blue, respectively. The side chains
at CDR positions that were randomized in the libraries are
shown. Side chains that do not make contact with hVEGF are
colored white. Tyrosine side chains that make contacts with
hVEGF are colored red, whereas all other contacting side chains
are colored blue. The hVEGF molecules are shown in the same
orientation in both panels.
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.R.Bradbury,
S.Sidhu,
S.Dübel,
and
J.McCafferty
(2011).
Beyond natural antibodies: the power of in vitro display technologies.
|
| |
Nat Biotechnol,
29,
245-254.
|
 |
|
|
|
|
 |
D.Lipovsek
(2011).
Adnectins: engineered target-binding protein therapeutics.
|
| |
Protein Eng Des Sel,
24,
3-9.
|
 |
|
|
|
|
 |
N.Monroe,
G.Sennhauser,
M.A.Seeger,
C.Briand,
and
M.G.Grütter
(2011).
Designed ankyrin repeat protein binders for the crystallization of AcrB: Plasticity of the dominant interface.
|
| |
J Struct Biol,
174,
269-281.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
O.Sharabi,
A.Dekel,
and
J.M.Shifman
(2011).
Triathlon for energy functions: Who is the winner for design of protein-protein interactions?
|
| |
Proteins,
79,
1487-1498.
|
 |
|
|
|
|
 |
S.Newstead,
D.Drew,
A.D.Cameron,
V.L.Postis,
X.Xia,
P.W.Fowler,
J.C.Ingram,
E.P.Carpenter,
M.S.Sansom,
M.J.McPherson,
S.A.Baldwin,
and
S.Iwata
(2011).
Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2.
|
| |
EMBO J,
30,
417-426.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Koldobskaya,
E.M.Duguid,
D.M.Shechner,
N.B.Suslov,
J.Ye,
S.S.Sidhu,
D.P.Bartel,
S.Koide,
A.A.Kossiakoff,
and
J.A.Piccirilli
(2011).
A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination.
|
| |
Nat Struct Mol Biol,
18,
100-106.
|
 |
|
|
|
|
 |
B.J.Hackel,
and
K.D.Wittrup
(2010).
The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold.
|
| |
Protein Eng Des Sel,
23,
211-219.
|
 |
|
|
|
|
 |
B.Li,
L.Zhao,
C.Wang,
H.Guo,
L.Wu,
X.Zhang,
W.Qian,
H.Wang,
and
Y.Guo
(2010).
The protein-protein interface evolution acts in a similar way to antibody affinity maturation.
|
| |
J Biol Chem,
285,
3865-3871.
|
 |
|
|
|
|
 |
C.M.Brawley,
S.Uysal,
A.A.Kossiakoff,
and
R.S.Rock
(2010).
Characterization of engineered actin binding proteins that control filament assembly and structure.
|
| |
PLoS One,
5,
e13960.
|
 |
|
|
|
|
 |
D.J.Martin,
and
M.Ramirez-Alvarado
(2010).
Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.
|
| |
Amyloid,
17,
129-136.
|
 |
|
|
|
|
 |
D.Wu,
J.Sun,
T.Xu,
S.Wang,
G.Li,
Y.Li,
and
Z.Cao
(2010).
Stacking and energetic contribution of aromatic islands at the binding interface of antibody proteins.
|
| |
Immunome Res,
6,
S1.
|
 |
|
|
|
|
 |
L.Borras,
T.Gunde,
J.Tietz,
U.Bauer,
V.Hulmann-Cottier,
J.P.Grimshaw,
and
D.M.Urech
(2010).
Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies.
|
| |
J Biol Chem,
285,
9054-9066.
|
 |
|
|
|
|
 |
M.P.Greving,
P.E.Belcher,
C.W.Diehnelt,
M.J.Gonzalez-Moa,
J.Emery,
J.Fu,
S.A.Johnston,
and
N.W.Woodbury
(2010).
Thermodynamic additivity of sequence variations: an algorithm for creating high affinity peptides without large libraries or structural information.
|
| |
PLoS One,
5,
e15432.
|
 |
|
|
|
|
 |
M.Umetsu,
T.Nakanishi,
R.Asano,
T.Hattori,
and
I.Kumagai
(2010).
Protein-protein interactions and selection: generation of molecule-binding proteins on the basis of tertiary structural information.
|
| |
FEBS J,
277,
2006-2014.
|
 |
|
|
|
|
 |
S.Birtalan,
R.D.Fisher,
and
S.S.Sidhu
(2010).
The functional capacity of the natural amino acids for molecular recognition.
|
| |
Mol Biosyst,
6,
1186-1194.
|
 |
|
|
|
|
 |
Z.S.Derewenda
(2010).
Application of protein engineering to enhance crystallizability and improve crystal properties.
|
| |
Acta Crystallogr D Biol Crystallogr,
66,
604-615.
|
 |
|
|
|
|
 |
C.J.Farady,
B.D.Sellers,
M.P.Jacobson,
and
C.S.Craik
(2009).
Improving the species cross-reactivity of an antibody using computational design.
|
| |
Bioorg Med Chem Lett,
19,
3744-3747.
|
 |
|
|
|
|
 |
J.Gao,
S.S.Sidhu,
and
J.A.Wells
(2009).
Two-state selection of conformation-specific antibodies.
|
| |
Proc Natl Acad Sci U S A,
106,
3071-3076.
|
 |
|
|
|
|
 |
T.Shibui,
T.Kobayashi,
K.Kanatani,
H.Koga,
S.Misawa,
T.Isomura,
and
T.Sasaki
(2009).
In vitro selection of scFv and its production: an application of mRNA display and wheat embryo cell-free and E. coli cell production system.
|
| |
Appl Microbiol Biotechnol,
84,
725-732.
|
 |
|
|
|
|
 |
V.Burke,
C.Williams,
M.Sukumaran,
S.S.Kim,
H.Li,
X.H.Wang,
M.K.Gorny,
S.Zolla-Pazner,
and
X.P.Kong
(2009).
Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.
|
| |
Structure,
17,
1538-1546.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
X.Xiao,
Y.Feng,
B.K.Vu,
R.Ishima,
and
D.S.Dimitrov
(2009).
A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors.
|
| |
Biochem Biophys Res Commun,
387,
387-392.
|
 |
|
|
|
|
 |
B.A.Manjasetty,
A.P.Turnbull,
S.Panjikar,
K.Büssow,
and
M.R.Chance
(2008).
Automated technologies and novel techniques to accelerate protein crystallography for structural genomics.
|
| |
Proteomics,
8,
612-625.
|
 |
|
|
|
|
 |
C.W.Cobaugh,
J.C.Almagro,
M.Pogson,
B.Iverson,
and
G.Georgiou
(2008).
Synthetic antibody libraries focused towards peptide ligands.
|
| |
J Mol Biol,
378,
622-633.
|
 |
|
|
|
|
 |
J.A.Boyer,
and
A.L.Lee
(2008).
Monitoring aromatic picosecond to nanosecond dynamics in proteins via 13C relaxation: expanding perturbation mapping of the rigidifying core mutation, V54A, in eglin c.
|
| |
Biochemistry,
47,
4876-4886.
|
 |
|
|
|
|
 |
J.D.Ye,
V.Tereshko,
J.K.Frederiksen,
A.Koide,
F.A.Fellouse,
S.S.Sidhu,
S.Koide,
A.A.Kossiakoff,
and
J.A.Piccirilli
(2008).
Synthetic antibodies for specific recognition and crystallization of structured RNA.
|
| |
Proc Natl Acad Sci U S A,
105,
82-87.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.L.Miller,
J.Le Coq,
A.Hodes,
R.Barbalat,
J.F.Miller,
and
P.Ghosh
(2008).
Selective ligand recognition by a diversity-generating retroelement variable protein.
|
| |
PLoS Biol,
6,
e131.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.G.Presta
(2008).
Molecular engineering and design of therapeutic antibodies.
|
| |
Curr Opin Immunol,
20,
460-470.
|
 |
|
|
|
|
 |
R.N.Gilbreth,
K.Esaki,
A.Koide,
S.S.Sidhu,
and
S.Koide
(2008).
A dominant conformational role for amino acid diversity in minimalist protein-protein interfaces.
|
| |
J Mol Biol,
381,
407-418.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Koide,
R.N.Gilbreth,
K.Esaki,
V.Tereshko,
and
S.Koide
(2007).
High-affinity single-domain binding proteins with a binary-code interface.
|
| |
Proc Natl Acad Sci U S A,
104,
6632-6637.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.R.Cooper,
T.Boczek,
K.Grelewska,
M.Pinkowska,
M.Sikorska,
M.Zawadzki,
and
Z.Derewenda
(2007).
Protein crystallization by surface entropy reduction: optimization of the SER strategy.
|
| |
Acta Crystallogr D Biol Crystallogr,
63,
636-645.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.Fuh
(2007).
Synthetic antibodies as therapeutics.
|
| |
Expert Opin Biol Ther,
7,
73-87.
|
 |
|
|
|
|
 |
I.Benhar
(2007).
Design of synthetic antibody libraries.
|
| |
Expert Opin Biol Ther,
7,
763-779.
|
 |
|
|
|
|
 |
O.Kirillova,
M.Chruszcz,
I.A.Shumilin,
T.Skarina,
E.Gorodichtchenskaia,
M.Cymborowski,
A.Savchenko,
A.Edwards,
and
W.Minor
(2007).
An extremely SAD case: structure of a putative redox-enzyme maturation protein from Archaeoglobus fulgidus at 3.4 A resolution.
|
| |
Acta Crystallogr D Biol Crystallogr,
63,
348-354.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Nauli,
S.Farr,
Y.J.Lee,
H.Y.Kim,
S.Faham,
and
J.U.Bowie
(2007).
Polymer-driven crystallization.
|
| |
Protein Sci,
16,
2542-2551.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.S.Sidhu,
and
A.A.Kossiakoff
(2007).
Exploring and designing protein function with restricted diversity.
|
| |
Curr Opin Chem Biol,
11,
347-354.
|
 |
|
|
|
|
 |
A.Whitty,
and
G.Kumaravel
(2006).
Between a rock and a hard place?
|
| |
Nat Chem Biol,
2,
112-118.
|
 |
|
|
|
|
 |
C.Kiss,
H.Fisher,
E.Pesavento,
M.Dai,
R.Valero,
M.Ovecka,
R.Nolan,
M.L.Phipps,
N.Velappan,
L.Chasteen,
J.S.Martinez,
G.S.Waldo,
P.Pavlik,
and
A.R.Bradbury
(2006).
Antibody binding loop insertions as diversity elements.
|
| |
Nucleic Acids Res,
34,
e132.
|
 |
|
|
|
|
 |
J.A.McIntyre,
D.R.Wagenknecht,
and
W.P.Faulk
(2006).
Redox-reactive autoantibodies: detection and physiological relevance.
|
| |
Autoimmun Rev,
5,
76-83.
|
 |
|
|
|
|
 |
J.C.Almagro,
V.Quintero-Hernández,
M.Ortiz-León,
A.Velandia,
S.L.Smith,
and
B.Becerril
(2006).
Design and validation of a synthetic VH repertoire with tailored diversity for protein recognition.
|
| |
J Mol Recognit,
19,
413-422.
|
 |
|
|
|
|
 |
S.S.Sidhu,
and
F.A.Fellouse
(2006).
Synthetic therapeutic antibodies.
|
| |
Nat Chem Biol,
2,
682-688.
|
 |
|
|
|
|
 |
G.Pál,
S.Y.Fong,
A.A.Kossiakoff,
and
S.S.Sidhu
(2005).
Alternative views of functional protein binding epitopes obtained by combinatorial shotgun scanning mutagenesis.
|
| |
Protein Sci,
14,
2405-2413.
|
 |
|
|
|
|
 |
H.R.Hoogenboom
(2005).
Selecting and screening recombinant antibody libraries.
|
| |
Nat Biotechnol,
23,
1105-1116.
|
 |
|
|
|
|
 |
R.A.Wilkinson,
C.Piscitelli,
M.Teintze,
L.A.Cavacini,
M.R.Posner,
and
C.M.Lawrence
(2005).
Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
|
| |
J Virol,
79,
13060-13069.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.L.Rich,
and
D.G.Myszka
(2005).
Survey of the year 2004 commercial optical biosensor literature.
|
| |
J Mol Recognit,
18,
431-478.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |
|